Pharmbio Korea Co., Ltd.
🇰🇷South Korea
- Country
- 🇰🇷South Korea
- Ownership
- Private
- Established
- 1999-05-01
- Employees
- 101
- Market Cap
- -
- Website
- http://www.pharmbio.co.kr
Clinical Trials
10
Active:0
Completed:4
Trial Phases
4 Phases
Phase 1:2
Phase 3:4
Phase 4:1
+1 more phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (9 trials with phase data)• Click on a phase to view related trials
Phase 3
4 (44.4%)Not Applicable
2 (22.2%)Phase 1
2 (22.2%)Phase 4
1 (11.1%)Evaluation of the Pharmacokinetics of "PBK_M2301" in Healthy Adults
Not Applicable
Recruiting
- Conditions
- Healthy Volunteers
- Interventions
- Drug: PBK_M2301 (levodropropizine + Pelargonium sidoides extract)Drug: R1_PBK_M2301 (levodropropizine)Drug: R2_PBK_M2301 (Pelargonium sidoides extract)
- First Posted Date
- 2025-09-08
- Last Posted Date
- 2025-09-12
- Lead Sponsor
- Pharmbio Korea Co., Ltd.
- Target Recruit Count
- 32
- Registration Number
- NCT07161180
- Locations
- 🇰🇷
H+ Yangji Hospital, Seoul, Seoul, South Korea
A Study to Evaluate Safety and Efficacy of PBK_M2502
Not Applicable
Not yet recruiting
- Conditions
- Intestinal DiseaseColonic DiseasesGastrointestinal DiseaseDigestive System Disease
- Interventions
- Drug: PBK_M2502 1-DayDrug: PBK_M2502 2-Day
- First Posted Date
- 2025-08-11
- Last Posted Date
- 2025-08-11
- Lead Sponsor
- Pharmbio Korea Co., Ltd.
- Target Recruit Count
- 110
- Registration Number
- NCT07114406
- Locations
- 🇰🇷
Kyung Hee University Hospital at Gangdong, Seoul, Gangdong-gu, Korea, Republic of
Drug-Drug Interaction Between R1_PBK_M2301 and R2_PBK_M2301 in Healthy Adults
Phase 1
Completed
- Conditions
- Drug-Drug Interaction Healthy Volunteers
- Interventions
- Drug: R1_PBK_M2301(Levocloperastine 60mg)Drug: R2_PBK_M2301 (Pelargonium sidoides extract)
- First Posted Date
- 2025-06-12
- Last Posted Date
- 2025-09-12
- Lead Sponsor
- Pharmbio Korea Co., Ltd.
- Target Recruit Count
- 24
- Registration Number
- NCT07017335
- Locations
- 🇰🇷
H+ Yangji Hospital, Seoul, Seoul, South Korea
Study to Evaluate the Efficacy and Safety of PBK_L2201 in Postmenopausal Women With Osteoporosis
- First Posted Date
- 2023-12-04
- Last Posted Date
- 2023-12-04
- Lead Sponsor
- Pharmbio Korea Co., Ltd.
- Target Recruit Count
- 60
- Registration Number
- NCT06154187
- Locations
- 🇰🇷
The Catholic University of Korea Yeouido Saint Mary's Hospital, Seoul, Korea, Republic of
A Study to Evaluate Safety and Efficacy of PBK_M2101
Phase 3
Recruiting
- Conditions
- Intestinal DiseaseDigestive System DiseaseColonic DiseasesGastrointestinal Disease
- Interventions
- First Posted Date
- 2023-06-28
- Last Posted Date
- 2023-06-28
- Lead Sponsor
- Pharmbio Korea Co., Ltd.
- Target Recruit Count
- 246
- Registration Number
- NCT05923918
- Locations
- 🇰🇷
Seoul Asan Medical Center, Seoul, Korea, Republic of
- Prev
- 1
- 2
- Next
News
No news found